Document Detail

Demonstrating bioequivalence using clinical endpoint studies.
MedLine Citation:
PMID:  22413789     Owner:  NLM     Status:  In-Data-Review    
Bermingham, E., del Castillo, J. R. E., Lainesse, C., Pasloske, K., Radecki, S. Demonstrating bioequivalence using clinical endpoint studies. J. vet. Pharmacol. Therap.35 (Suppl. 1), 31-37. For drug products not amenable to blood level studies, clinical endpoint studies have been used as an indirect measure of formulation difference in bioavailability between test and reference products. However, clinical endpoint studies are not as sensitive in detecting formulation differences as blood level studies and offer numerous challenges to both regulatory authorities and sponsors. The objective of this article is not to suggest new regulatory policies, but to explore new methodologies and alternative solutions to clinical endpoint bioequivalence (BE) studies, which are used when a blood level study is not considered to be appropriate. To achieve this objective, this article identifies situations where a clinical endpoint study might be appropriate, lists the advantages and disadvantages of this type of study design, and discusses possible alternative solutions. It is concluded that future evidence-based research is needed to explore new methodologies such as clinical trial simulations of various study designs, new statistical methods, and new in vitro methods to demonstrate BE.
E Bermingham; J R E Del Castillo; C Lainesse; K Pasloske; S Radecki
Related Documents :
15319259 - A method for estimating stochastic noise in large genetic regulatory networks.
25273129 - Applying association mapping and genomic selection to the dissection of key traits in e...
9268549 - Phosphate adsorption on hematite, kaolinite, and kaolinite-hematite (k-h) systems as de...
18611429 - Modeling the fitness of plant morphologies across three levels of complexity.
20388839 - High-resolution cardiovascular function confirms functional orthology of myocardial con...
19964089 - Performance evaluation of an algorithm for the identification of time-varying joint sti...
22483879 - Artificial neural networks combined with experimental design: a "soft" approach for che...
23072469 - A two-component mass balance model for calibration of solid-phase microextraction fiber...
20491599 - Indicators and quality specifications for strategic and support processes related to th...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of veterinary pharmacology and therapeutics     Volume:  35 Suppl 1     ISSN:  1365-2885     ISO Abbreviation:  J. Vet. Pharmacol. Ther.     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-03-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7910920     Medline TA:  J Vet Pharmacol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  31-7     Citation Subset:  IM    
Copyright Information:
Published 2012. This article is a U.S. Government work and is in the public domain in the USA.
Division of Therapeutic Drugs for Non-Food Animals, FDA Center of Veterinary Medicine, Rockville, MD, USA Department de Biomédecine Vétérinaire, Université de Montréal, St-Hyacinthe, Québec, QC, Canada Clinical Evaluation Division, Veterinary Drugs Directorate, Health Canada, Ottawa, ON, Canada Jurox Pty Ltd., Rutherford, NSW, Australia Statistical Consultant, Petoskey, MI, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pharmacokinetics and pharmacodynamics of stereoisomeric drugs with particular reference to bioequiva...
Next Document:  Should licking behavior be considered in the bioavailability evaluation of transdermal products?